Table 1

Event risks, costs and quality of life during 12 months of therapy

Parameter	Sweden		UK		Germany		Brazil
Parameter	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel
Probability non-fatal MI clinical pathway	0.0535	0.0619	0.0535	0.0619	0.0535	0.0619	0.0535	0.0619
Probability non-fatal stroke clinical pathway	0.0119	0.0110	0.0119	0.0110	0.0119	0.0110	0.0119	0.0110
Probability death clinical pathway	0.0642	0.0811	0.0642	0.0811	0.0642	0.0811	0.0642	0.0811
Probability no MI or stroke clinical pathway	0.8704	0.8460	0.8704	0.8460	0.8704	0.8460	0.8704	0.8460
Healthcare cost of non-fatal MI clinical pathway (€)*	23 653	23 994	18 365	18 606	14 777	14 964	4401	4482
Healthcare cost of non-fatal stroke clinical pathway (€)*	22 925	23 266	16 731	16 972	13 193	13 380	2865	2946
Healthcare cost of death clinical pathway (€)*	17 227	17 568	12 267	12 508	9 921	10 108	2496	2577
Healthcare cost of no MI or stroke clinical pathway (€)*	10 294	10 635	8193	8434	6681	6856	1998	2079
Daily cost of study drug (€)†	2.21	0.06	2.27	0.07	2.91	0.35	2.34	0.52
QALY non-fatal MI clinical pathway	0.7667	0.7697	0.7667	0.7697	0.7667	0.7697	0.7667	0.7697
QALY non-fatal stroke clinical pathway	0.7388	0.7418	0.7388	0.7418	0.7388	0.7418	0.7388	0.7418
QALY death clinical pathway	0.2414	0.2445	0.2414	0.2445	0.2414	0.2445	0.2414	0.2445
QALY no MI or stroke clinical pathway	0.8422	0.8452	0.8422	0.8452	0.8422	0.8452	0.8422	0.8452

*Healthcare costs excluding drug costs, study drug costs are entered as separate parameters.
†2012 prices.
MI, myocardial infarction; QALY, quality-adjusted life-year.